AstraZeneca Rejects Pfizer’s Final $117bn Bid

LONDON, May 19- British drugs giant AstraZeneca rejected on Monday a final takeover bid from US rival Pfizer worth $117 billion, saying it undervalued the firm and created uncertainty and risk for shareholders. Shares in AstraZeneca plunged by about 14.0 percent in early trading. Pfizer had made an improved and final offer worth 85 billion […]

Read more here Capital Business